LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.

Publication

Author(s):

Aurpibul L, Lumbiganon P, Kolasaraksa P, Hansudewechakul R, Sa-Nguanmoo P, Taeprasert P, Bunupuradah T, Poovorawan Y, Sirisanthana V, Puthanakit T.

Pub Title:

HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents.

Pub Date:

Sep 30 2012

Pub Region(s):

Asia-Pacific

Journal Issue:

9

Page Number:
943-7

Journal:

Title: 
Pediatr Infect Dis J
Link: 
http://journals.lww.com/pidj/pages/articleviewer.aspx?year=2012&issue=09000&article=00020&type=abstract

PubMed: 22592516
Pub PDF: PDF icon 22592516.pdf

Abstract
OBJECTIVES
: This study aimed to determine the prevalence of hepatitis B virus (HBV) coinfection and HBV seropositivity in perinatally HIV-infected adolescents. A secondary objective was to describe the clinical characteristics of adolescents with chronic HBV/HIV coinfection.

MATERIALS AND METHODS: Multicenter cross-sectional study of perinatally HIV-infected adolescents aged 12-25 years. HBV surface antigen, surface antibody (anti-HBs) and core antibody (anti-HBc) were measured. Coinfection was defined as having persistently positive HBV surface antigen. Seroprotective antibody from immunization was defined as having anti-HBs ≥10 mIU/mL with negative anti-HBc. HBV DNA quantitation and rtM204V/I mutation analysis (lamivudine resistance-associated mutation) were performed in adolescents with chronic HBV infection.

RESULTS: From November 2010 to March 2011, 521 patients were enrolled. Mean (SD) of CD4 lymphocyte count was 685 (324) cells/μL. The prevalence of HBV/HIV coinfection was 3.3% (95% confidence interval: 1.9-5.2%). Protective antibody against HBV was found in 18% of population, and this was significantly higher among adolescents who received than those who did not receive HBV revaccination after receiving antiretroviral therapy (93% versus 6%, P < 0.01). Among adolescents with chronic HBV infection, 88% have received lamivudine; however, 69% have HBV DNA >10 copies/mL and 75% had the rtM204V/I mutation.

CONCLUSIONS: The prevalence of HBV coinfection in HIV-infected Thai adolescents was 3.3%. Most HIV-infected adolescents had no HBV protective antibody; therefore, revaccination with HBV vaccine is encouraged. The high prevalence of HBV-lamivudine resistance underscores the importance of HBV screening prior to antiretroviral therapy initiation to guide the selection of optimal regimen for coinfected children.

PMID: 22592516 [PubMed - indexed for MEDLINE]

PMCID: PMC3511890

 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Aurpibul L, Lumbiganon P, Kolasaraksa P, Hansudewechakul R, Sa-Nguanmoo P, Taeprasert P, Bunupuradah T, Poovorawan Y, Sirisanthana V, Puthanakit T. HIV and Hepatitis B coinfection among perinatally HIV-infected Thai adolescents. Pediatr Infect Dis J. 2012 Sep;31(9):943-7. PubMed PMID: 22592516; PubMed Central PMCID: PMC3511890.